Last reviewed · How we verify
Triple-targeted CAR-T Therapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Triple-targeted CAR-T Therapy (Triple-targeted CAR-T Therapy) — Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Triple-targeted CAR-T Therapy TARGET | Triple-targeted CAR-T Therapy | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Triple-targeted CAR-T Therapy CI watch — RSS
- Triple-targeted CAR-T Therapy CI watch — Atom
- Triple-targeted CAR-T Therapy CI watch — JSON
- Triple-targeted CAR-T Therapy alone — RSS
Cite this brief
Drug Landscape (2026). Triple-targeted CAR-T Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/triple-targeted-car-t-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab